Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development.
Samuel L NeffThomas H HamptonKatja KoeppenSharanya SarkarCasey J LatarioBenjamin D RossBruce A StantonPublished in: mSystems (2023)
) pathogens are of considerable medical concern due to their virulence and exceptional ability to develop antibiotic resistance. New kinds of antimicrobial therapies are urgently needed to treat patients for whom existing antibiotics are ineffective. The Rocket-miR application predicts targets of human miRNAs in bacterial and fungal pathogens, rapidly identifying candidate miRNA-based antimicrobials. The application's target audience are microbiologists that have the laboratory resources to test the application's predictions. The Rocket-miR application currently supports 24 recognized human pathogens that are relevant to numerous diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), urinary tract infections, and pneumonia. Furthermore, the application code was designed to be easily extendible to other human pathogens that commonly cause hospital-acquired infections.
Keyphrases
- chronic obstructive pulmonary disease
- endothelial cells
- cell proliferation
- long non coding rna
- staphylococcus aureus
- antimicrobial resistance
- cystic fibrosis
- gram negative
- urinary tract infection
- induced pluripotent stem cells
- long noncoding rna
- healthcare
- pseudomonas aeruginosa
- pluripotent stem cells
- newly diagnosed
- escherichia coli
- intensive care unit
- emergency department
- acute respiratory distress syndrome
- electronic health record
- peritoneal dialysis
- biofilm formation
- acute care
- mechanical ventilation